Navigation Links
Sagent Pharmaceuticals Announces U.S. FDA Tentative Approval of Additional Adenosine Injection, USP Vial Presentations
Date:4/22/2010

SCHAUMBURG, Ill., April 22 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration had granted tentative approval of adenosine injection, USP, the generic equivalent of Astellas Pharmaceuticals' Adenoscan®, in 60 mg per 20 mL and 90 mg per 30 mL vials.  IMS data indicate that the 2009 U.S. innovator market for these adenosine presentations approximated $124 million.  The Company plans to launch the product upon expiry of applicable innovator patents.

Upon approval, adenosine will be launched under Sagent's partnership with Strides Arcolab.  Under this venture, Sagent and Strides Arcolab are jointly developing, supplying and marketing more than 25 injectable products for the U.S. market.  Strides is responsible for developing and manufacturing injectable products that Sagent will market in the United States.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products.  Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients.  

To Discover Injectables Excellence™ and learn more about Sagent, please visit www.SagentPharma.com.  

About Strides Arcolab, Ltd.

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 14 manufacturing facilities across 6 countries with marketing presence in more than 60 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore. Additional information is available at the company's website at www.stridesarco.com.


'/>"/>
SOURCE Sagent Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sagent Pharmaceuticals Announces Launch of Adenosine Injection, USP, in 6 mg per 2 mL Single-Dose Vials
2. Sagent Pharmaceuticals Launches Vinorelbine Injection, USP
3. Sagent Pharmaceuticals to Present at Two Upcoming Financial Conferences
4. Sagent Pharmaceuticals Launches Pamidronate Disodium Injection
5. Sagent Pharmaceuticals to Present at Piper Jaffray Health Care Conference
6. Sagent Pharmaceuticals Bolsters Antibiotics Offering With Two Product Launches
7. Sagent Pharmaceuticals Announces FDA Approval of Labetalol Hydrochloride Injection, USP
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... 22, 2017  Lilac Corp, the company that ... launch of a new website . The ... a clinical study that showed surprising clearance of ... in individuals suffering from HPV warts, precancerous, or ... are no other treatments that clear the virus. ...
(Date:5/18/2017)... N.J. , May 17, 2017  Bayer announced ... oncology portfolio will be presented at the 53 rd ... Oncology (ASCO), taking place June 2-6 in ... presented at ASCO span prostate, colorectal, liver and thyroid ... analysis from the Phase II CHRONOS-1 trial of copanlisib ...
(Date:5/12/2017)... -- The China and Canada joint tech company Laughing ... energy and detergent, and features a powerful disinfection process. ... machine that washes and sanitizes women,s panties or babies, cloth diapers ... ... not require an external water inlet. ...
Breaking Medicine Technology:
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... London, May ... honored to serve earlier this month as a Guest Speaker and Contributor to a ... Royal Family and Common Purpose. , Walter Schindler and SAIL ...
(Date:5/23/2017)... Rosa, CA (PRWEB) , ... May 23, 2017 , ... ... mosquito season underway in Sonoma County. While officials call for diligence, asking homeowners to ... are looking at potential health concerns. Along with the annoying buzz of mosquitos is ...
(Date:5/23/2017)... , ... May 23, 2017 , ... ... leading equipment provider in the modern ART laboratory, to provide hands-on training utilizing ... Lauderdale, Florida. , NextGen LifeLabs, a MedTech Group Purchasing vendor , will ...
(Date:5/23/2017)... ... , ... New patients from Charleston, SC, are now welcome to receive a ... SC, with or without a referral. A full mouth reconstruction can transform the appearance ... in Charleston, SC. Those who suffer from gum disease, misaligned teeth or jaw pain ...
(Date:5/23/2017)... ... 2017 , ... New patients with symptoms of gum disease in ... gum disease treatments from the doctors at Art of Dentistry, without first receiving a ... the importance of receiving qualified treatment in order to avoid systemic health effects associated ...
Breaking Medicine News(10 mins):